Technical Analysis for VIR - Vir Biotechnology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | -1.50% | |
| Multiple of Ten Bullish | Other | -1.50% | |
| Wide Bands | Range Expansion | -1.50% | |
| Gapped Up | Strength | -1.50% | |
| Crossed Above 200 DMA | Bullish | -2.08% | |
| Multiple of Ten Bullish | Other | -2.08% | |
| Wide Bands | Range Expansion | -2.08% | |
| Gapped Up | Strength | -2.08% | |
| Crossed Above 50 DMA | Bullish | 1.02% | |
| Wide Bands | Range Expansion | 1.02% |
| Alert | Time |
|---|---|
| 200 DMA Resistance | 25 minutes ago |
| Fell Below 200 DMA | 25 minutes ago |
| Fell Below Previous Day's Low | 25 minutes ago |
| Down 1% | 25 minutes ago |
| Fell Below 10 DMA | 25 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: 05/29/2024
Vir Biotechnology, Inc. Description
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Immunology Infectious Diseases Influenza Coronavirus Therapeutic Products Hepatitis B Immunodeficiency Hepatitis B Virus Dimm Treatment Of Hepatitis Tuberculosis Alnylam Pharmaceuticals Treatment Of Hepatitis B Medimmune Serious Infectious Diseases Therapeutic
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.48 |
| 52 Week Low | 7.61 |
| Average Volume | 906,864 |
| 200-Day Moving Average | 10.02 |
| 50-Day Moving Average | 9.57 |
| 20-Day Moving Average | 8.99 |
| 10-Day Moving Average | 9.81 |
| Average True Range | 0.48 |
| RSI (14) | 59.68 |
| ADX | 23.58 |
| +DI | 32.71 |
| -DI | 19.43 |
| Chandelier Exit (Long, 3 ATRs) | 9.15 |
| Chandelier Exit (Short, 3 ATRs) | 9.05 |
| Upper Bollinger Bands | 10.77 |
| Lower Bollinger Band | 7.21 |
| Percent B (%b) | 0.79 |
| BandWidth | 39.57 |
| MACD Line | 0.20 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.1637 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.81 | ||||
| Resistance 3 (R3) | 10.84 | 10.62 | 10.68 | ||
| Resistance 2 (R2) | 10.62 | 10.42 | 10.60 | 10.63 | |
| Resistance 1 (R1) | 10.32 | 10.29 | 10.21 | 10.28 | 10.59 |
| Pivot Point | 10.09 | 10.09 | 10.04 | 10.07 | 10.09 |
| Support 1 (S1) | 9.79 | 9.89 | 9.68 | 9.76 | 9.45 |
| Support 2 (S2) | 9.57 | 9.77 | 9.55 | 9.41 | |
| Support 3 (S3) | 9.27 | 9.57 | 9.36 | ||
| Support 4 (S4) | 9.23 |
